Literature DB >> 14516708

Effect of steroidal and non-steroidal anti-inflammatory drugs in combination with long-acting oxytetracycline on non-specific immunity of calves suffering from enzootic bronchopneumonia.

Dariusz Bednarek1, Barbara Zdzisińska, Marian Kondracki, Martyna Kandefer-Szerszeń.   

Abstract

The aim of this paper was to compare the effect of flumethasone and meloxicam in combination with oxytetracycline on clinical and immunological parameters of calves suffering from enzootic bronchopneumonia. The study was performed on 30 Black-and-White Lowland Breed calves with clinical signs of enzootic bronchopneumonia divided randomly into three equal groups and, respectively, treated with-Group I: oxytetracycline and meloxicam; Group II: oxytetracycline and flumethasone; Group III (control): oxytetracycline only. Treatment of calves with the combination of oxytetracycline and meloxicam (Group I) caused a significantly faster, in comparison to other groups, improvement in the clinical illness index score (CIIS: cough, nasal discharge, dyspnea, depression and anorexia) and a faster normalization of body temperature. A slow decrease in white blood cell (WBC) count, the number of neutrophils, MID (mixed number of monocytes, eosinophils and basophils) and in the individual number of monocytes (CD14/CD45 positive cells) was observed in Groups I and III. In the blood of the calves which received oxytetracycline and flumethasone (Group II), leukocytosis, neutrophilia and monocytosis with concomitant lymphopenia and a low number of T cells (CD2+) was observed. Moreover, the calves treated with flumethasone exhibited a decrease in gamma-globulin concentration, and phagocytic parameters. Both drugs, flumethasone and meloxicam slightly decreased tumor necrosis factor (TNF) but meloxicam slightly increased the levels of interferon (IFN) in sera and in bronchoalveolar lavages (BALs). These results suggest that the combination of meloxicam with an antibiotic in calves suffering from enzootic bronchopneumonia is superior to the antibiotic alone and also to the combination of the antibiotic with flumethasone.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14516708     DOI: 10.1016/s0378-1135(03)00203-7

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  6 in total

1.  Comparative therapeutic effect of steroidal and non-steroidal anti-inflammatory drugs on pro-inflammatory cytokine production in water buffalo calves (Bubalus bubalis) naturally infected with bronchopneumonia: a randomized clinical trial.

Authors:  Mohamed Abdo Rizk; Motamed Elsayed Mahmoud; Shimaa Abd El-Salam El-Sayed; Doaa Salman
Journal:  Trop Anim Health Prod       Date:  2017-08-22       Impact factor: 1.559

2.  Adverse effects of a 10-day course of ibuprofen in Holstein calves.

Authors:  P Walsh; F R Carvallo Chaigneau; M Anderson; N Behrens; H McEligot; B Gunnarson; L J Gershwin
Journal:  J Vet Pharmacol Ther       Date:  2016-02-14       Impact factor: 1.786

3.  In vitro effects of meloxicam on the number, Foxp3 expression, production of selected cytokines, and apoptosis of bovine CD25+CD4+ and CD25-CD4+ cells.

Authors:  Tomasz Maślanka; Jerzy Jan Jaroszewski
Journal:  J Vet Sci       Date:  2013-04-30       Impact factor: 1.672

4.  Comparative evaluation of different therapeutic protocols for contagious caprine pleuropneumonia in Himalayan Pashmina goats.

Authors:  Mohd Iqbal Yatoo; Oveas Raffiq Parray; Muheet Mir; Riyaz Ahmed Bhat; Hamid Ullah Malik; Mujeeb Ur Rehman Fazili; Sabia Qureshi; Masood Salim Mir; Raja Wasim Yousuf; Noor Alam Tufani; Kuldeep Dhama; Shah Tauseef Bashir
Journal:  Trop Anim Health Prod       Date:  2019-05-10       Impact factor: 1.893

5.  Wheezing after the use of acetaminophen and or ibuprofen for first episode of bronchiolitis or respiratory tract infection.

Authors:  Paul Walsh; Stephen J Rothenberg
Journal:  PLoS One       Date:  2018-09-13       Impact factor: 3.240

6.  Clinical-pathological findings of otitis media and media-interna in calves and (clinical) evaluation of a standardized therapeutic protocol.

Authors:  I Bertone; C Bellino; G L Alborali; A Cagnasso; G Cagnotti; E Dappiano; M Lizzi; M Miciletta; A Ramacciotti; P Gianella; A D'Angelo
Journal:  BMC Vet Res       Date:  2015-12-03       Impact factor: 2.741

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.